Ignite Creation Date:
2024-05-06 @ 4:59 PM
Last Modification Date:
2024-10-26 @ 2:20 PM
Study NCT ID:
NCT05155566
Status:
COMPLETED
Last Update Posted:
2024-01-26
First Post:
2021-12-09
Brief Title:
Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HRHER2- AdvancedMetastatic Breast Cancer In Real World Settings
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HORMONE RECEPTOR POSITIVE HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE HRHER2- AdvancedMetastatic Breast Cancer In Real World Settings
Status:
COMPLETED
Status Verified Date:
2023-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To describe patient demographics clinical characteristics treatment patterns and clinical outcomes of adult female patients who have received palbociclib combination treatments as first line therapy regardless of combination partner and labelled use in real world settings across Latin America
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| IRIS LATAM | OTHER | Alias Study Number | None |